Table 1 Background and operative characteristics of the patients
Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
OPD | LPD | P value | OPD | LPD | P value | |
Patients,n | 53 | 58 | 44 | 44 | ||
Age,n(%) | 57.1 ± 9.0 | 58.9 ± 9.7 | 0.294 | 57.2 ± 9.0 | 59.1 ± 9.8 | 0.360 |
Sex,n(%) | 0.558 | 0.189 | ||||
Male | 30(56.6%) | 36(62.1%) | 30(68.2%) | 24(54.5%) | ||
Female | 23(43.4%) | 22(37.9%) | 14(31.8%) | 20(45.5%) | ||
Weight(kg) | 62.8 ± 4.6 | 62.4 ± 4.7 | 0.679 | 63.0 ± 4.4 | 62.1 ± 4.6 | 0.357 |
BMI(kg/2) | 21.2 ± 2.3 | 21.1 ± 2.2 | 0.941 | 21.2 ± 2.3 | 21.0 ± 2.2 | 0.600 |
Hepatic function index | ||||||
ALT | 56.6 ± 14.5 | 61.1 ± 13.1 | 0.230 | 55.9 ± 15.9 | 59.8 ± 12.5 | 0.151 |
ALB | 32.8 ± 3.9 | 33.5 ± 2.5 | 0.402 | 33.1 ± 2.3 | 33.7 ± 2.3 | 0.254 |
TB | 129.0 ± 31.0 | 128.1 ± 20.4 | 0.851 | 129.5 ± 33.3 | 128.1 ± 20.7 | 0.821 |
Preoperative chemotherapy | 1.000 | 1.000 | ||||
Yes | 0(0%) | 0(0%) | 0(0%) | 0(0%) | ||
No | 53(100%) | 58(100%) | 44(100%) | 44(100%) | ||
Presence of biliary stent | 1.000 | 1.000 | ||||
Yes | 52(98.1%) | 56(96.5%) | 43(97.7%) | 42(95.5%) | ||
No | 1(1.9%) | 2(3.5%) | 1(2.3%) | 2(4.5%) | ||
Pancreatic duct diameter(mm) | 0.954 | 1.000 | ||||
≤ 3 | 18(34.0%) | 20(34.5%) | 18(40.9%) | 18(40.9%) | ||
> 3 | 35(66.0%) | 38(65.5%) | 26(59.1%) | 26(59.1%) | ||
Pancreatic texture(n,%) | 0.252 | 1.000 | ||||
Hard | 13(24.5%) | 20(34.5%) | 13(29.5%) | 13(29.5%) | ||
Soft | 40(75.5%) | 38(65.5%) | 31(70.5%) | 31(70.5%) | ||
Operative characteristics | ||||||
Operation time (min) | 258.7 ± 29.4 | 299.1 ± 48.0 | < 0.001 | 261.7 ± 30.4 | 299.7 ± 45.9 | < 0.001 |
PJ-time (min) | 27.4 ± 6.4 | 29.9 ± 4.1 | 0.017 | 27.4 ± 6.1 | 29.9 ± 4.3 | 0.030 |
Blood loss(ml) | 129.3 ± 60.0 | 135.2 ± 75.7 | 0.653 | 125.8 ± 59.7 | 133.9 ± 69.1 | 0.562 |
Hospital stay (days) | 16.6 ± 2.5 | 12.8 ± 2.7 | < 0.001 | 16.9 ± 2.4 | 13.1 ± 2.9 | < 0.001 |
Radicality(n,%) | 1.000 | 1.000 | ||||
R0 | 52(98.1%) | 56(96.5%) | 43(97.7%) | 42(95.5%) | ||
R1/2 | 1(1.9%) | 2(3.5%) | 1(2.3%) | 2(4.5%) | ||
Primary tumor origin(n%) | 0.990 | 0.975 | ||||
Pancreatic head tumor | 3(5.7%) | 4(6.9%) | 3(6.8%) | 4(9.1%) | ||
Ampullary adenocarcinoma | 23(43.4%) | 26(44.8%) | 23(52.3%) | 21(47.7%) | ||
Distal CBD adenocarcinoma | 6(11.3%) | 7(12.1%) | 6(13.6%) | 5(11.4%) | ||
Duodenal adenocarcinoma | 5(11.3%) | 6(6.3%) | 5(11.4%) | 5(11.4%) | ||
Other malignancy | 4(9.4%) | 5(8.6%) | 4(9.1%) | 4(9.1%) | ||
Benign lesions | 12(22.6%) | 10(17.2%) | 3(6.8%) | 5 (11.4%) | ||
FRS | 0.917 | 0.372 | ||||
Negligible(0) | 2(3.8%) | 1(1.7%) | 2(4.5%) | 1(2.3%) | ||
Low risk (1–2) | 16(30.2%) | 18(31.1%) | 16(36.4%) | 16(36.4%) | ||
Intermediate risk(3–6) | 32(60.3%) | 35(60.3%) | 26(59.1%) | 25(56.8%) | ||
High risk(7–10) | 3(5.7%) | 4(6.9%) | 0(0%) | 2(4.5%) | ||